Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
US Department of Justice
Cantor Fitzgerald
Boehringer Ingelheim
Cipla
McKesson
Covington
Julphar
Merck

Generated: April 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,220,767

« Back to Dashboard

Which drugs does patent 7,220,767 protect, and when does it expire?

Patent 7,220,767 protects ZOMIG and is included in one NDA.

Protection for ZOMIG has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirty-nine patent family members in twenty-eight countries.
Summary for Patent: 7,220,767
Title:Pharmaceutical formulations containing zolmitriptan
Abstract:A pharmaceutical formulation of the 5HT1-agonist, zolmitriptan, for use in intranasal administration. The formulation is useful in treating migraine and related disorders.
Inventor(s): Dearn; Alan Roy (Hertfordshire, GB), Williamson; Sarah Louise (Hertfordshire, GB), Summers; John Simon (Hertfordshire, GB), Coomber; Trevor John (Hertfordshire, GB)
Assignee: AstraZeneca AB (Sodertalje, SE)
Application Number:10/854,959
Patent Claim Types:
see list of patent claims
Composition; Formulation; Device;

Drugs Protected by US Patent 7,220,767

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-003 Sep 16, 2013 RX Yes No ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Astrazeneca ZOMIG zolmitriptan SPRAY;NASAL 021450-004 Sep 30, 2003 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,220,767

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9928578.5Dec 03, 1999

Non-Orange Book US Patents Family Members for Patent 7,220,767

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,750,237 Pharmaceutical formulations containing zolmitriptan ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

QuintilesIMS
AstraZeneca
Mallinckrodt
McKesson
Argus Health
Teva
Boehringer Ingelheim
Colorcon
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.